George Widhopf

Title(s)Project Scientist, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein. Biomedicines. 2024 Jul 16; 12(7). Xian J, Sinha N, Girgis C, Oh CS, Cring MR, Widhopf GF, Kipps TJ. PMID: 39062146; PMCID: PMC11274362.
      View in: PubMed   Mentions:
    2. A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer. Breast Cancer Res. 2024 02 26; 26(1):32. Shatsky RA, Batra-Sharma H, Helsten T, Schwab RB, Pittman EI, Pu M, Weihe E, Ghia EM, Rassenti LZ, Molinolo A, Cabrera B, Breitmeyer JB, Widhopf GF, Messer K, Jamieson C, Kipps TJ, Parker BA. PMID: 38408999; PMCID: PMC10895766.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    3. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia. Leukemia. 2022 06; 36(6):1609-1618. Ghia EM, Rassenti LZ, Choi MY, Quijada-Álamo M, Chu E, Widhopf GF, Kipps TJ. PMID: 35418613; PMCID: PMC9162914.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    4. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. Leukemia. 2021 06; 35(6):1621-1630. Hasan MK, Ghia EM, Rassenti LZ, Widhopf GF, Kipps TJ. PMID: 33097837; PMCID: PMC8062590.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    5. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis. NPJ Breast Cancer. 2019; 5:35. Hasan MK, Widhopf GF, Zhang S, Lam SM, Shen Z, Briggs SP, Parker BA, Kipps TJ. PMID: 31667337; PMCID: PMC6814774.
      View in: PubMed   Mentions: 14  
    6. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019 09 26; 134(13):1084-1094. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. PMID: 31409670; PMCID: PMC6764264.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    7. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc Natl Acad Sci U S A. 2019 01 22; 116(4):1370-1377. Zhang S, Zhang H, Ghia EM, Huang J, Wu L, Zhang J, Lam S, Lei Y, He J, Cui B, Widhopf GF, Yu J, Schwab R, Messer K, Jiang W, Parker BA, Carson DA, Kipps TJ. PMID: 30622177; PMCID: PMC6347692.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    8. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2019 03; 33(3):653-661. Hasan MK, Rassenti L, Widhopf GF, Yu J, Kipps TJ. PMID: 30568170; PMCID: PMC6462876.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    9. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 01; 22(6):951-959.e3. Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. PMID: 29859176; PMCID: PMC7001723.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCellsCTClinical Trials
    10. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget. 2018 May 15; 9(37):24731-24736. Yu J, Chen Y, Chen L, Zhang L, Rassenti LZ, Widhopf GF, Kipps TJ. PMID: 29872501; PMCID: PMC5973864.
      View in: PubMed   Mentions: 15     Fields:    
    11. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018 07 12; 132(2):170-178. Hasan MK, Yu J, Widhopf GF, Rassenti LZ, Chen L, Shen Z, Briggs SP, Neuberg DS, Kipps TJ. PMID: 29678828; PMCID: PMC6043980.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    12. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10731-10736. Rassenti LZ, Balatti V, Ghia EM, Palamarchuk A, Tomasello L, Fadda P, Pekarsky Y, Widhopf GF, Kipps TJ, Croce CM. PMID: 28923920; PMCID: PMC5635897.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    13. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017 12; 31(12):2608-2614. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, Wu R, Rassenti LZ, Widhopf GF, Shen Z, Briggs SP, Kipps TJ. PMID: 28465528; PMCID: PMC5670032.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    14. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 12 22; 128(25):2931-2940. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. PMID: 27815263; PMCID: PMC5179332.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCells
    15. Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. Int J Hematol Oncol. 2016 May; 5(1):27-35. Manouchehri S, Ibsen S, Wright J, Rassenti L, Ghia EM, Widhopf GF, Kipps TJ, Heller MJ. PMID: 30302201; PMCID: PMC6171991.
      View in: PubMed   Mentions: 11  
    16. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016 Feb; 126(2):585-98. Yu J, Chen L, Cui B, Widhopf GF, Shen Z, Wu R, Zhang L, Zhang S, Briggs SP, Kipps TJ. PMID: 26690702; PMCID: PMC4731190.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansAnimalsCells
    17. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. Choi MY, Widhopf GF, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ. PMID: 26297272; PMCID: PMC4548279.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    18. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One. 2015; 10(6):e0128151. Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJ. PMID: 26030772; PMCID: PMC4451012.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    19. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014 Dec 02; 111(48):17266-71. Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF, Zhang Z, Wu CC, Chen L, Wu R, Schwab R, Carson DA, Kipps TJ. PMID: 25411317; PMCID: PMC4260559.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansAnimalsCells
    20. Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis. 2014 Jul; 35(12-13):1828-36. Sonnenberg A, Marciniak JY, Skowronski EA, Manouchehri S, Rassenti L, Ghia EM, Widhopf GF, Kipps TJ, Heller MJ. PMID: 24723219; PMCID: PMC4214757.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    21. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice. Proc Natl Acad Sci U S A. 2014 Jan 14; 111(2):793-8. Widhopf GF, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps TJ. PMID: 24379361; PMCID: PMC3896194.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    22. Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem. 2014 Mar; 60(3):500-9. Sonnenberg A, Marciniak JY, Rassenti L, Ghia EM, Skowronski EA, Manouchehri S, McCanna J, Widhopf GF, Kipps TJ, Heller MJ. PMID: 24270796; PMCID: PMC4114224.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    23. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. PLoS One. 2013; 8(6):e65203. Que X, Widhopf GF, Amir S, Hartvigsen K, Hansen LF, Woelkers D, Tsimikas S, Binder CJ, Kipps TJ, Witztum JL. PMID: 23840319; PMCID: PMC3688726.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    24. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013 Jun 15; 73(12):3649-60. Cui B, Zhang S, Chen L, Yu J, Widhopf GF, Fecteau JF, Rassenti LZ, Kipps TJ. PMID: 23771907; PMCID: PMC3832210.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansAnimalsCells
    25. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood. 2012 Mar 08; 119(10):2293-301. Steininger C, Widhopf GF, Ghia EM, Morello CS, Vanura K, Sanders R, Spector D, Guiney D, Jäger U, Kipps TJ. PMID: 22234695; PMCID: PMC3311256.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    26. Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia. J Immunol. 2011 Jun 01; 186(11):6338-44. Ghia EM, Widhopf GF, Rassenti LZ, Kipps TJ. PMID: 21525382; PMCID: PMC7015129.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    27. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2010 Nov 02; 107(44):18956-60. Zhang W, Kater AP, Widhopf GF, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ. PMID: 20956327; PMCID: PMC2973856.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    28. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood. 2009 Nov 12; 114(20):4469-76. Enzler T, Kater AP, Zhang W, Widhopf GF, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ. PMID: 19755673.
      View in: PubMed   Mentions: 31     Fields:    Translation:Animals
    29. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res. 2009 Mar; 33(3):368-76. Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ. PMID: 18640719; PMCID: PMC2692898.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    30. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15; 111(10):5101-8. Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. PMID: 18326815; PMCID: PMC2384137.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    31. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3047-52. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF, Rassenti LZ, Cantwell MJ, Prussak CE, Carson DA, Kipps TJ. PMID: 18287027; PMCID: PMC2268582.
      View in: PubMed   Mentions: 168     Fields:    Translation:HumansAnimalsCells
    32. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 2008 Mar 15; 111(6):3137-44. Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ. PMID: 17675554; PMCID: PMC2265453.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    33. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity. 2006 Sep; 25(3):403-15. Enzler T, Bonizzi G, Silverman GJ, Otero DC, Widhopf GF, Anzelon-Mills A, Rickert RC, Karin M. PMID: 16973390.
      View in: PubMed   Mentions: 78     Fields:    Translation:AnimalsCells
    34. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004 Oct 15; 104(8):2499-504. Widhopf GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. PMID: 15217828.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCells
    35. Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation. J Immunol. 2004 Feb 15; 172(4):2092-9. Widhopf GF, Brinson DC, Kipps TJ, Tighe H. PMID: 14764674.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    36. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002 Dec 15; 100(13):4609-14. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. PMID: 12393534.
      View in: PubMed   Mentions: 138     Fields:    Translation:HumansCells
    37. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001 Dec 03; 194(11):1639-47. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. PMID: 11733578; PMCID: PMC2193523.
      View in: PubMed   Mentions: 270     Fields:    Translation:Humans
    38. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J Allergy Clin Immunol. 2001 Sep; 108(3):417-23. Horner AA, Widhopf GF, Burger JA, Takabayashi K, Cinman N, Ronaghy A, Spiegelberg HL, Raz E. PMID: 11544462.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    39. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol. 2001 Jan 01; 166(1):95-102. Widhopf GF, Kipps TJ. PMID: 11123281.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    40. Characterization and genomic mapping of a novel leader peptide associated with the human VH4-21 (VH4-34) gene segment. Ann N Y Acad Sci. 1995 Sep 29; 764:62-71. Widhopf GF, Pascual V, Baer R, Capra JD. PMID: 7486591.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells